CSE:VEGI

Boosh To Introduce Shelf Stable Products To National Grocers 3 Months Ahead Of Schedule

Boosh Plant-Based Brands Inc. (CSE:VEGI) ("Boosh" or the "Company") announces it is scheduled to begin shipping their first shelf stable entrees by the end of September, 2021, approximately three months earlier than anticipated.

In February, 2021, Boosh acquired plant-based shelf stable vegan cheese assets from a Canadian limited partnership called Vegan Canteen ("VC"). In addition to receiving a variety of assets including, but not limited to, plant-based powdered cheese recipes which are anticipated to be incorporated into numerous Boosh products, the Company is developing the products to enhance their flavour with even more "cheesy punch" to match the Boosh brand expectations. The two new cheese flavors include "Better Cheddar" and "Nacho Cheese."

"We loved the Vegan Canteen vegan cheese powder, but we pushed for even more cheesy flavour so now it's over the top delicious. To stay true to our healthy mantra, the first three ingredients are nutritional yeast, pea protein and tapioca compared to many of our competitors in which their first three ingredients are sugar, oil and salt. With Boosh, you feel like you are eating something to curb that "fast food" craving yet it's actually very healthy and leaves you feeling energetic and satisfied," states Connie Marples, founder and president of Boosh. Connie continues, "In addition to the cheese products the Vegan Canteen division developed a vegan gluten-free pepperoni that, during taste tests while served on pizza, fooled non-vegans into thinking it was a meat-based pepperoni." The pepperoni is expected to launch the first quarter of 2022."

Connie concludes, "I'm extremely pleased with the results we have gotten with our enhanced cheeses, and with our tasty, nutritional and fun-to-eat pepperoni. It's so flavourful, and even crisps up when cooked just like meat-based pepperoni! And to compliment all of that, the texture in your mouth is very similar to pepperoni because of the plant-based proteins and fibre."

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer
Telephone: (833) 882-6674

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food, is the gateway to experiencing high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals which are sold throughout Canada, and in the summer will be expanding our meals to include three refrigerated products. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88260

News Provided by Newsfile via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types

- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. Central Time, on Monday, November 18th, 2024, at the American Heart Association Scientific Sessions 2024. Dr. S. Allen Luis, Co-Director, Pericardial Diseases Clinic and Associate Professor of Medicine, Department of Cardiovascular Medicine at the Mayo Clinic, will present on behalf of the MAvERIC-Pilot investigators.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC

DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less

Latest Press Releases

Related News

×